Sheng Gao

2024

• Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study

  Taylor P, Schett G, Huizinga T, Wang Q, Ibrahim F, Zhou B, Liva S, Shaik J, Xiong Y, Leu J, Panchakshari R, Loza M, Ma K, Dhatt H, Cella R, Karyekar C, Cuff C, Gao S, Fei K. Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study. RMD Open 2024, 10: e004278. PMID: 38942592, PMCID: PMC11227837, DOI: 10.1136/rmdopen-2024-004278.

  Peer-Reviewed Original Research

  MeSH Keywords and Concepts

• Modulation of Interleukin‐23 Signaling With Guselkumab in Biologic‐Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis

  Siebert S, Coates L, Schett G, Raychaudhuri S, Chen W, Gao S, Seridi L, Chakravarty S, Shawi M, Lavie F, Sharaf M, Zimmermann M, Kollmeier A, Xu X, Rahman P, Mease P, Deodhar A. Modulation of Interleukin‐23 Signaling With Guselkumab in Biologic‐Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis. Arthritis & Rheumatology 2024, 76: 894-904. PMID: 38253404, DOI: 10.1002/art.42803.

  Peer-Reviewed Original Research

  Altmetric

  Concepts